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INTRODUCTION
1INTRODUCTION
There are approximately   400 million   hepatitis B virus (HBV)
carriers in the world.    Till 1981, hepatitis B patients relied on serology
assays (1). “E” antigen (HBeAg) was a marker of infectivity.  Initially
assays to quantify HBV DNA polymerase activity was done and later only
HBV DNA level estimation could be done. Method used was hybridization
techniques.  Spontaneous e antigen seroconversion is seen in the course of
chronic HBV infection.
	Course of B positive individuals had 2 stages as defined initially.
First stage has e antigen, and HBV DNA detectable. Second stage does not
have HBeAg, immeasurable DNA, and passive liver disease. Second stage
patients are “healthy” carriers   who are non replicative.
2Our country India lies in intermediate zone with a carrier rate of 3-7
% (2). India presents with HBV in early childhood.  Means of transmitting
infection by percutaneous method is common like sexual route.
3Our study aimed to determine common routes of infection and
clinical profile of HBV patients.  Various parameters were assessed for e
antigen seroconversion and its correlation was analysed. Clinical response
was also analysed with the antiviral drug and differences in responses of
both e antigen  groups were analysed.
AIM
4AIM
1. To predict the HBeAg seroconversion in relation with HBsAg
quantification in patients with chronic HBV infection with antiviral
treatment
2.  Clinical profile of Chronic  HBV infection
3. Clinical response of Chronic HBV infection patients with antiviral
drug in a Tertiary centre
REVIEW OF LITERATURE
5REVIEW OF LITERATURE
HBV INFECTION -  Natural history :
64 stages of chronic infection include
1.  Tolerance stage -   e antigen positive, high hepatitis B deoxy nucleic
acid, stable enzymes and stable histology (3). E seroconversion is
limited. Prognosis is good.
2. Clearance – e antigen positive , alternating HBV deoxyribonucleic
acid  and dormant inflammation
Rate of spontaneous e antigen clearance is 10 to 20 % (4)
3. Inactive - e antigen negative, antibody to e antigen present, stable
ALT and immeasurable Deoxy ribo nucleic acid levels.
4. Fourth stage -  e antigen negative , antibody to e antigen positive ,
measurable DNA levels , increased enzymes and fibrosis.(5)
Cirrhosis is seen in two to six % in e antigen positive. In e antigen
negative it is around eight to ten % (6). High levels of cirrhosis in e negative
occur due to elderly age who has progressive liver disease. Advancement
to cirrhosis occurs due to alcohol, co infection with other viruses and
depending on genotype.
7                                 Natural course of HBV infection
8CHRONIC HBV INFECTION AND HCC:
HCC incidence is one % for non-cirrhotic carriers and 2% to 3% in
patients with cirrhosis.(7)
Other  factors which may progress to HCC include
Co-infection with HCV(8),
Family history of HCC(9),
Alcohol intake,
High levels of HBV replication,
And core promoter mutations.(10)
9 Ways and means of Hepatitis B transmitting routes
Ethnicity and high risk behaviour are important routes of
transmitting infection.
Knowing of risk factors should be done .
Transmitting routes of infection are :
Blood transfusion
Percutaneous
Sexual (11)
Perinatal (12)
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Vaccination against hepatitis B is the mainstay. Universal
vaccination to all new born is practised now(13). HCC is reduced in juvenile
group because of vaccination. Vaccination has resulted in a major fall in
HCC even in this young age group (14).
 Hepatitis B immunoglobulin  and vaccine has better efficacy (98%)
compared to vaccine alone (15).
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Plasma and recombinant are two types of vaccine available. Vaccine is
administered intramuscularly 0 , 1 and 6 months . Dose is  10 to 20
microgram for adults.(16)
12
                   Currently available vaccines their dosage and schedule.
Anti HBs level more than ten IU / L is arrived in more than 95 % of
recipients(17).
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Various factors for failure of vaccine.
Clinical symptoms :
Fatigue is more common than poor appetite and malaise. Right
upper quadrant pain is generally but of low grade. Physical examination
may reveal hepato splenomegaly . Decompensation progresses to jaundice
, ascites and peripheral edema.  Serum bilirubin and enzymes are usually
normal in inactive carrier state . enzymes become elevated during
exacerbations of disease .
 Extra hepatic syndromes (18) are seen in both acute and chronic
forms. They are arthritis , dermatitis , glomerulo nephritis ,polyarthritis
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nodosa(19), cryoglobulinemia papular acrodermatitis and polymyalgia
rheumatica. They are secondary to circulating immune complexes.
DIAGNOSIS:
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Patients do not have any symptoms until they have been progressed
to progressive stage . Screening high risk person is essential for early
diagnosis .
High risk persons need to be screened
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HBsAg  is important for the diagnosis . Continuation of positivity
even after 6 months denotes chronic infection. C anigen cannot be detected
in blood but antibody can be seen. Immunoglobulin G  presence presents
an idea whether the the  person has been recovered or chronically infected
.E antigen is derived from precore protein indicating replication and
infectivity. Seroconversion is  followed by reduction in DNA levels .If it
doesn’t happen it may be due to precore or core promoter HBV
variants (20).
DNA is a marker of viremia which could be done by realtime PCR
assays (21). They identify less than ten international units. Regular
monitoring is done to see which phase the patient belongs and to see the
response during treatment. Serum HBV DNA levels are expressed in IU/ml
to ensure comparability.
PRE THERAPEAUTIC ASSESSMENT :
Assessment of the  liver disease needs to be done. HBV serological
markers is done for first degree relatives and sexual partners of patients
They are vaccinated if tested negative. Normal ALT levels are seen in
immune tolerant phase and inactive carriers.E negative people have
intermittently normal ALT level. Routine liver function tests are needed to
assess the patient .Enzymes  are a crucial determinant for starting treatment
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while albumin , globulin are predictors to exclude decompensation.  A
liver biopsy needed  to determine the degree of necroinflammation and
fibrosis since histology can assist the decision to start treatment.  It may
rile other cause for liver disease. Adverse effects are  very low 1 in four
thousand or ten thousand. A liver biopsy is not required with clinical
evidence of cirrhosis or in those in whom treatment is indicated
irrespective of stage of fibrosis. serum markers and transient elastography
can assess hepatic fibrosis and  complement or to avoid a liver biopsy.
Transient elastography has high diagnostic accuracy.
TREATMENT OF CHRONIC HEPATITIS B :
The aims of treatment of chronic hepatitis B are to achieve
a)  continued  suppression of HBV replication
b)  Remission of liver disease.
They should be decided whether to start or defer treatment .It depends
on the grade of liver disease and its future progression to cirrhosis and
hepatocellular carcinoma. (22 - 26).  Low risk patients should be monitored at
regular intervals.
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Algorithm for treatment of  CHB
Deferred groups for treatment  are young patients who are in tolerant
phase and inactive carrier phase. These group of patients should br
regularly followed up with blood tests.  IFNs are given predefined
durations, while nucleoside analogues ( NA) are usually administered until
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certain  endpoints are achieved. This occurs due to immunomodulatory
effects . For HBeAg-positive patients, viral suppression can be sustained in
50% to 90% patients if treatment is suspended  after HBeAg
seroconversion  is achieved. For HBeAg-negative patients, relapse is
common  even when HBV DNA has been suppressed to undetectable
levels for more than a year; thus, the endpoint for suspending  treatment is
unclear .
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Both antiviral and immune modulation effect has been seen with
interferon(27). It has been used from 1992 . It is effective even after a short
treatment. There is poorer acceptance because of low DNA suppression
and adverse effects. IFN-alpha induced HBeAg clearance in e positive
appears to be durable in 80% to 90% of patients with a follow-up period of
4 to 8 years(28).
Pegylated interferon is more potent. Attachment of polyethylene
glycol reduces absorption. Renal clearance is also reduced thereby
prolonging its half life. Results of treatment response ranged from 38% to
90% in treated patients compared with only 0% to 37% of controls (29) e
antigen negative patients. It is given for 48 weeks for both e antigen
positive and negative patients .Data is not available for increased
effectiveness which may be due to effect on viral replication or immune
modulatory function (30).
 Both Interferons have similar side effect profiles. The most
common side effect is influenza-like illness: fever, chills, headache,
malaise and emotional lability.
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Peg interferon – advantages and diadvantages
Lamivudine was approved by 1998 .  Monotherapy  has good effect in
suppressing replication of the virus and in stopping progression of the liver
disease . It is easy to administer and free of side effects. Increment in
resistance is seen as duration of treatment progresses . Thirty eight percent
at end of 2 years and sixty five percent at 5 years is seen (31). It is more
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common when associated with  retro viral patients where treatment would
have been started earlier.
Adefovir is acyclic phosphonate nucleotide analog of  AMP .
Approved in 2002 based on the trials of  various continents . (32). E antigen
seroconversion and non detectability of DNA is increased during the
second year. (33). Adverse events noted with this drug are
1.Renal impairment
2.Fanconi’s anemia (34)
3. Hypophosphatemia
Selective inhibition of  replication is seen with entecavir. Approved
in 2005 based on results showing better efficacy than lamivudine. It is
better than lamivudine in regards to histological improvement, reduction to
undetectable HBV DNA, reduction in mean HBV DNA level from
baseline , ALT normalization, and HBeAg seroconversion (35 )
Telbivudine is an L nucleoside analog  of thymidine. Drug has
activity against HBV DNA polymerase.It is efficiently phosphorylated by
cellular kinases to form the active triphosphate form. Active form has an
intracellular half-life of 14 hours. Telbivudine-5'-triphosphate inhibits
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HBV DNA polymerase (reverse transcriptase) and thus HBV replicationt is
more potent than lamivudine in trials(36) .
YMDD motif is the place where mutations occur . It is well tolerated
when single therapy is used.  It is used safely. Complaints  of  myopathy
and peripheral neuropathy are  reported. Peripheral neuropathy common
when telbivudine was used in combination with pegIFN(37) .
TENOFOVIR :
Tenofovir disoproxil fumarate is a nucleotide analogue initially
approved for the treatment of HIV infection and later  approved for the
treatment of chronic hepatitis B in 2008. Tenofovir is structurally similar
to adefovir.  Similar rates of histologic response and HBeAg
seroconversion  was seen when compared to adefovir(38).   Dose should be
adjusted with creatinine clearance  < 50 mL/min. Adverse effect note with
tenofovir are
1. Renal impairment
2. Fanconi syndrome
3. Osteomalcia
24
Approved dose – antiviral agents
Characteristics of Interferon and NA
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Resistance is the major concern with oral antiviral agents . In the
current time , increased rates of  resistance and entecavir and tenofovir
offers less resistance. Early manifestation of antiviral resistance is
virologic breakthrough . it is mainly due tomedication noncompliance.
DNA levels are low initially but compensatory mutations restore
replication fitness leading to a progressive increase in serum HBV DNA .
Drug having  low rate of genotypic resistance should be started and
compliance reinforced. Combination therapy has shown good results.
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In treatment naïve patients , resistance is more seen in lamivudine
and it increases every year. While entecavir (39)and tenofovir is very less.In
patients with  resistance to lamivudine  entecavir proved good results but
resistance increased by years in those patients also(40).
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Rescue therapy for resistance
HBeAg SEROCONVERSION :
E antigen  clearance and seroconversion is used for
suppression of HBV,
reduced infectivity
improved clinical prognosis.
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E antigen seroconversion is the desirable effect of treatment .Other
points  in  treatment are enzyme normal levels , immeasurable DNA and
clearance of e antigen. When treatment is continued for long after e antigen
clearance and conversion sustained virological response is good.They
should be closely monitored for relapse with follow-up testing of HBV
DNA and HBeAg for up to 2 years after discontinuation of NA
monotherapy.
Treatment is considered to stop when immeasurable DNA level is
documented on two separate occasions with six  months apart  .
Importance of  this period of consolidation therapy  reduces   risk of
relapse after HBeAg seroconversion. They may lead to HBsAg
seroclearance, which is the most desirable end point closest to a “cure.”
 Newer-generation oral NAs  provides a finite course of therapy for
individuals with HBeAg-positive CHB .E antigen seroconversion with low
DNA levels is the ideal goal in the management .
HBsAg QUANTIFICATION :
HBsAg is an important test that marks active infection with HBV
and also predict the clinical outcome of the infection. Detection of low
HBsAg and HBV DNA levels identify true inactive carriers who need
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neither strict follow up nor antiviral treatment. Based on HBsAg
quantification, a response-guided therapy in both HBeAg-positive and -
negative patients treated with Peg-IFN has been developed. According to
the data, therapy can be stopped at week 12 in primary non responders,
who become candidate to alternative therapies, such as unlimited
suppressive therapy with NA. Decline of serum HBsAg may also assist
NA-treated patients, mainly the HBeAg-positive ones, however, according
to slower kinetics than those related to Peg-IFN therapy. Because
progressive decline of HBsAg heralds clearance of HBsAg in all instances,
this may help increasing cost-effectiveness ratio of NA therapy.
MATERIALS  AND
METHODS
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MATERIALS AND METHODS
It is a prospective study conducted between October 2010 and April
2012 where consecutive patients with the diagnosis of Chronic HBV
infection undergoing medical treatment with antiviral Telbivudine from
our hospital were included. During this period patients started on treatment
for compensated CHB infection are included in this study.
A written consent was obtained from all the patients. Institute ethical
committee has approved the study.  All patients with compensated CHB
patients were included in the study.  All patients underwent a detailed
clinical evaluation at entry, with the following data:
Age, gender, duration of illness, details of treatment prior to
registration. Baseline demographic details such as age, gender, literacy,
socio economic status, alcohol intake, smoking, religion and occupation
were collected. Patient had baseline investigations such as Complete blood
count, Liver function test, Prothrombin time, International normalized
ratio, renal function test, HBsAg, Anti-HCV, ultra sonogram and
endoscopy.
A detailed history about the method of  transmission, identification
of chronic HBV infection was asked from history .A detailed clinical
examination was also performed in all patients which includes pallor,
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jaundice, and on per abdomen examination abdominal veins, liver and
spleen enlargement and ascites to exclude decompenation.
Upper gastrointestinal endoscopy and grading of the varices was
done in all patients. Grading of varices was done by using Sarin’s
classification.
Exclusion Criteria:
1.  Patients with decompensated chronic liver disease
2.  Patients who did not fit into the guidelines for treatment of chronic
infecton were not included.
Blood tests :
Haematological and biochemical workup included measurement of
haemoglobin , total leukocyte count , platelet count, prothrombin time and
liver function tests including bilirubin and liver enzymes. Special
investigations in relation to chronic HBV infection like HBeAg, HBV
DNA quantification, HBsAg quantification  , at baseline and at regular
intervals at 4,12, 24 and 48 weeks were done for follow up.
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Statistical analysis :
Quantitative data were expressed in Mean and Standard deviation.
Qualitative data were given in frequencies with their percentage.
Differences in clinical response at the end of 48 wks between e antigen
positive and negative patients  were analyzed by using Pearson Chi square
test/ student independent test as appropriate. P value less than 0.05 was
taken as statistically significant.
OBSERVATION AND
RESULTS
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OBSERVATION AND RESULTS
100 patients of chronic HBV infection (76 men, 24 women) were
enrolled in the study. Mean age of males who are HBeAg positive are 42.3
yrs and who are  e antigen negative are 44.3 years. Mean age of females
who are e antigen positive are 37.4 yrs and 41.2 yrs. Mean HBV DNA log
10  IU  /ml  was  6.25  in  e  positive  and  4.45  in  e  negative  patients  .  Mean
HBsAg log 10 IU/ml was 3.91 in e positive and 3.39 in e negative patients
. Mean ALT levels were 75 in e positive and 68 in e negative patients.
Fig 1. Gender distribution :
76%
24%
Male
Female
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Table 1 : Demographic characteristics of the study population
e Ag positive e Ag negative
No. of Pts 48 52
Sex                             Male 37 (77%) 39 (75%)
                                  Female 11 (23%) 13 (25%)
Mean age                  Male 42.3 yrs 44.3 yrs
                                  Female 37.4 yrs 41.2 yrs
Mean HBV DNA log 10 IU/ml 6.25 4.45
Mean HBsAg log 10 IU/ml 3.91 3.39
Mean ALT IU/ml 75 68
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Fig 2.  SOURCE OF INFECTION:
Unknown causes form in majority (36% ) followed by blood transfusion
(21%)  . Injection use and vertical transmission (16% each ) accounts for
further transmission .
21%
16%
7%
4%
16%
36%
Blood Transfusion
Injection Use
Sexual
Tatooing
Vertical
Unknown
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Fig. 3 : Detection of HBsAg
E antigen positivity was seen in 48 patients and e antigen negative
status seen in 52 patients.
48%
52% e Ag positive
e Ag negative
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Fig 4 :  USG Abdomen :
Patients had normal study in 89% and fatty liver in 11% of patients
by ultrasound
11%
89%
Fatty Liver
Normal Study
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Fig . 5 : Endoscopic findings :
92 % patients had normal study in endoscopy. 6 % had portal
hypertensive gastropathy and 2 % had oesophageal varices
2%
92%
6%
Esophageal Varices
Normal Study
PHG
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TABLE 1
 Prediction of HBeAg seroconversion in relation with HBsAg
quantification
  HBsAg<2890 IU/mL                                    HBeAg seroconversion
    Week 24                                                             non-HBeAg seroconversion
                                                                                 HBeAg seroconversion
             HBsAg>2890 IU/mL                                     Non-HBeAg seroconversion
        48
      n=23
     n=25
     n=16
    n=22
      n=7
    n= 3
40
HBsAg at
24 wk
Seroconverted Non
seroconversion
PPV NPV P
VALUE
<2890 16 7 0.70  0.88 0.05
>2890 3 22
HBsAg value at 24 weeks had a significant value at 2890 IU/ ml
.Hence patients were randomised to levels below or above 2890 and
according to seroconverted or non seroconverted. Among 23 patients with
HBsAg levels < 2890 IU/mL at week 24, 68 %  had HBeAg
seroconversion at the end of follow up. Among 25 patients with HBsAg
levels > 2890 IU/ mL at week 24, 13 % had HBeAg seroconversion at the
end of follow up (P = 0.05). Positive predictive value was 0.70 and
Negative predictive value was 0.88 .
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FIG 6 : Mean HBsAg  decline  in HBsAg patients
158581
28374 31668
21349 20044
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6945
2095 1346 10830
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Baseline wk 4 wk 12 wk 24 wk 48
e Seroconverted
Non e Seroconverted
Median HBsAg concentrations over time in patients are shown in
Figure 7. Among patients who achieved HBeAg seroconversion, HBsAg
level decreased consistently during treatment and remained at low levels
.Conversely, HBsAg in patients in the non-HBeAg seroconversion group
showed a slight decrease in HBsAg levels during therapy.
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Other factors in predicting e seroconversion:
COLUMN Total
1 2 P value
Age >40 14 10 24
<40 9 15 24
0.149
Vertical 2 16 18
Other 9 21 30
0.132
 ALT   >60
          <60
16
7
14
11
30
18
0.332
Various parameters were assessed for e antigen sero conversion.
Age, vertical transmission and ALT levels which were proven predictors
for e antigen seroconversion had an insignificant p value. P values for  age,
vertical transmission and ALT levels are 0.149 , 0.132 and 0.332
respectively
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Table 2: Response to Telbivudine in e positive patients:
Baseline Wk 4 Wk 12 Wk 24 Wk 48
Mean HBV DNA log 10
iu/ml 6.25 4.15 2.48 1.86
Mean HBV DNA log 10
iu/ml redn -2.09 -3.77 -4.39
PCR negativity < 300
copies/ml (n / %) 3 (6) 16 (33) 32 (66)
Mean HBsAg log 10
iu/ml 3.91 3.74 3.68 3.48 3.45
Mean HBsAg log 10
iu/ml redn -0.17 -0.23 -0.43 -0.46
Mean ALT levels 75 44
ALT normalization (n /
%) 28 (58)
e Seroconversion (n / %) 19  (39.5)
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Table 3 : response to Telbivudine in e negative patients
Baseline Wk 4 Wk
12
Wk
24
Wk
48
Mean HBV DNA log 10 IU/ml 4.45 2.55 2.01 1.54
Mean HBV DNA log 10 IU/ml
redn -1.9 -2.44 -2.9
PCR negativity < 300 copies/ml
(n / %) 26 (50)
32
(61.5)
43
(82.6)
Mean HBsAg log 10 IU/ml 3.39 3.44 3.46 3.31 3.32
Mean HBsAg log 10 IU/ml redn 0.05 0.07 -0.08 -0.07
Mean ALT levels 68 37.6
ALT normalization (n / %) 38 (73)
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HBV DNA SUPPRESSION PCR negativity (< 300 cp / ml)
6
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82.6
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Mean ALT Normalization (< 40 iu/ml) at 48 weeks
58
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e Ag positive e Ag negative
Series1
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Table 4: response at 48 weeks between e positive and negative
T df
Sig.
(2-ailed)
Mean
Differen
ce
95% Confidence
Interval of the
Difference
Lower Upper
hbv_48 1.144 98 .256 .292 -.2147 .7989
1.148 97.967 .254 .292 -.2127 .7968
cp_48 1.230 98 .222 .3140 -.19260 .82058
1.235 97.932 .220 .3140 -.19043 .81841
hbvred_48 -4.611 98 .000 -1.5268 -2.18382 -.86974
-4.609 97.137 .000 -1.5268 -2.18425 -.86931
hbsag_48 .823 98 .412 .129 -.1813 .4385
.819 93.715 .415 .129 -.1831 .4403
hbsred_48 -2.429 98 .017 -.3913 -.71090 -.07163
-2.398 84.732 .019 -.3913 -.71568 -.06685
alt_48 1.601 98 .113 6.39 -1.533 14.312
1.592 93.532 .115 6.39 -1.582 14.361
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MEAN HBV DNA log 10 IU / ml decline
6.25
4.15
2.48
1.86
4.45
2.55
2.01
1.54
0
2
4
6
8
10
12
Baseline wk 4 wk 24 wk 48
e Ag negative
E Ag positive
48
MEAN  HBsAg log 10 IU / ml decline
3.91
3.74
3.68
3.48
3.45
3.39
3.44
3.46
3.31 3.32
3
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9
4
Baseline Wk 4 Wk 12 Wk 24 Wk 48
e Ag positive
e Ag negative
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More patients did not record any adverse effect but minority of patients
experienced
Myalgia
Myopathy
Fatigue
resistance
DISCUSSION
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DISCUSSION
Chronic HBV infection is major burden to the community with
significant changes from simple chronic infection progressing to cirrhosis
and liver failure. However this complication primarily occurs in patients
who remained e antigen positive for a longer time. Hence treatment for
chronic HBV infection occurs is an important option to reduce HBV DNA
level and e antigen seroconversion. Few data have been published about
predictors of HBeAg seroconversion. In hepatitis B e antigen (HBeAg)
positive patients, the strongest predictor of HBeAg seroconversion is the
pretreatment alanine aminotransferase (ALT) level. Other factors include
high histologic activity index, low HBV DNA level, HBV genotypes A
and B . Few studies have been done to study the effect of HBsAg
quantification in relation to e antigen seroconversion.
Our study, based on information achieved from 100 patients from
chronic HBV infection in a tertiary centre in south India we tried to predict
the relation between HBsAg quantification and HBeAg seroconversion .
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Clinical profile of chronic HBV patients was done in relation to
mode of infection, identification of infection, radiological and endoscopic
findings of patients.
In our study, unknown factors were the cause for maximum mode of
transfusion followed by blood transfusion. This study was contrary in
terms being intravenous drug use being more common in  Ko YC, Chung
DC et al (41)
Hui Ma et al (42) demonstrated serum HBsAg and HBeAg are strong
predictors for sustained HBeAg seroconversion with pegylated interferon.
In our study we correlated HBsAG quantification with e antigen
seroconversion with telbivudine.
Hui ma et al had demonstrated a cut off value of 2890 IU / ml of
HBsAg at week 24 .In our study a statistical significant value was
identified as 2890. With cut off value of 2890, e seroconversion was found
to have positive predictive value of  of 0.70  , negative predictive value of
0.88 with p value of  0.05  . In contrary Hui ma et al demonstrated positive
predictive value at 0.40 and negative predictive value  of 1 with p value of
0.010 .
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In our study HBsAg level decreased consistently during treatment in
sero converted group when compared to non seroconverted group.This was
consistent with Hui ma et al .
Clinical and virological efficacy endpoints were evaluated
separately in the HBeAg-positive and HBeAg-negative patient populations
in Globe study. The primary endpoint at week 52 is suppression of HBV
DNA to <5 log10 copies/mL in addition with either loss of serum HBeAg
or ALT normalized. Secondary endpoints include histological response,
ALT normalization.
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Response at 48 weeks
Response parameter E positive E negative
Mean HBV DNA log 10
iu/ml redn
- 4.39 -2.9
PCR negativity < 300
copies/ml (/ %)
66% 82.6
ALT normalization
( / %)
58 73
e Seroconversion ( / %) 52 N.A
Our study found that HBsAg reduction at 48 weeks had significant
value in both e antigen positive and negative cases .Other values like ALT,
HBsAg , HBsAg reduction , HBV DNA copies and HBV DNA reduction
was not significant in both groups.
SUMMARY
54
SUMMARY
In the present study,
1. The most common mode of transmission was unidentified (36%)
followed by blood transfusion and vertical modes. ( 21%  and 16 %
respectively )
2. HBsAg quantification is an important predictor of e antigen
seroconversion with a p value of significance. ( p – 0.05)
3. Other factors expected to have importance like age, vertical and
ALT levels did not have any statistical significance. (0.14  , 0.13 ,
0.332 respectively)
4. Various parameters to assess clinical response at 48 weeks between
e antigen positive and negative were assessed. HBsAg reduction at
48 weeks seemed to have statistical significance. (p- 0.019)
CONCLUSION
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CONCLUSION
In conclusion, results of our study indicate that HBsAg
quantification  is a good predictor of  HBeAg seroconversion .Values for
the HBsAg quantification from this study need to be validated by
randomised  prospective studies . Other parameters like age , vertical
transmission and baseline ALT levels were not significant.
Applying HBsAg quantification though may not be cost effective it
appears to be a good predictor for e antigen seroconversion  but further
randomised studies are needed to evaluate the accurate prediction of e
antigen seroconversion in our population .
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ABBREVIATIONS
ABBREVIATIONS
HBV -         Hepatitis B virus
HBsAg  -         Hepatitis B surface antigen
HBeAg  -         Hepatitis e antigen
NAT -         Nucleic acid testing
IDU -         Intravenous drug use
HBIG -         Hepatitis B Immunoglobulin
NA -         Nucleoside analogue
RCT -         Randomised control trials
IFN -         Interferon
Rt -         Reverse Transcriptase
HCC -         Hepatocellular carcinoma
C antigen    -         Hepatitis B virus Core antigen
Anti HCV -         Antibody to hepatitis C virus
DNA         -  Deoxyribonucleic acid
PROFORMA
PROFORMA
Name:                        Age:                                        Sex:
MGE No:
D.O.R:
Resident of:  Chennai / other city (specify)
Type of house:  Pucca/hut/semiPer capita income:
Literacy status: studied up to: no education/I-V/VI-VIII/IX-
XII/college/professional/other courses
Occupation (as such):No. of children:
No. of adult family members:
Religion:  Hindu /Muslim /Christian/others (specify):
Smoker: - Present/Past/Never Alcohol:- Present/Past/Never
Identity of infection :
                                          Incidental
                                          screening
Source of infection :
vertical
                                     blood transfusion
                                     iv drug abuse
                                     sexual
                                     unknown
O/E
Pallor:                  Jaundice:             Clubbing:            Cyanosis:
Fever:              Pedal edema:                       Asterixis:
Liver cell failure features :
Parotidomegaly:
Gynaecomastia:
Spider angioma:
Dupuytran’s contracture:
Palmar erythema:
 Testicular atrophy:
Per abdomenVeins
Liver span:Consistency/edges/surfaceSpleen size
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MASTER CHART
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Sex - 1 – male , 2- female
E antigen              -  1-positive , 2- negative
Usg abdomen        - 1- normal study , 2 – fatty liver
Endoscopy            - 1 – normal , 2 – PHG , 3- esophageal varices
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1 VIJAYALAKSHMI 1684/10 2 unknown 2 38 24 215000 5.33 1247000 6.1 6450 3.81 3000 3.48 17400 4.24 -1.86 5385 3.73 -0.08 2000 3.3 11600 4.06 -2.03 3172 3.5 -0.31 16 1 normal study negative nil positive incidental
2 JAYADEEPAK 5715/09 21 1 vertical 1 68 42 170000000 8.23 986000000 8.99 4500 3.65 847 2.93 4912.6 3.69 -5.3 5620 3.75 0.1 20 1.3 116 2.06 -6.93 4222 3.63 -0.03 36 1 normal study positive nil positive screening
3 VEERARAGHAVAN 2117/09 58 1 tatooing 2 64 32 22000 4.34 127600 5.11 12000 4.08 20 1.3 116 2.06 -3.04 19545 4.29 0.21 20 1.3 116 2.06 -3.04 8721 3.94 -0.14 40 1 normal study negative nil positive incidental
4 GOMATHI 4200/08 36 2 sexual 2 52 32 19446 4.29 112786.8 5.05 3414 3.53 234 2.37 1357.2 3.13 -1.92 5432 3.73 0.2 20 1.3 116 2.06 -2.99 3421 3.53 0 32 1 normal study negative nil positive incidental
5 SIVAPRAKASAM 1250/10 69 1 unknown 2 72 23 22431 4.35 130099.8 5.11 3437 3.54 20 1.3 116 2.06 -3.05 2103 3.32 -0.21 20 1.3 116 2.06 -3.05 2312 3.36 -0.17 24 2 PHG negative nil positive incidental
6 PARASURAM 1392/04 44 1 injection use 1 72 45 100929 5 585388.2 5.77 13652 4.14 20 1.3 116 2.06 -3.7 2400 3.38 -0.75 20 1.3 116 2.06 -3.7 1321 3.12 -1.01 32 1 normal study negative nil positive incidental
7 PREMKUMAR 4630/10 47 1 unknown 1 63 92 23990660 7.38 139145828 8.14 4737 3.68 242 2.38 1403.6 3.15 -5 2000 3.3 -0.37 20 1.3 116 2.06 -6.08 1674 3.22 -0.45 54 1 normal study negative nil positive incidental
8 RAMAN 4352/10 50 1 unknown 2 82 19 2400 3.38 13920 4.14 1604 3.21 20 1.3 116 2.06 -2.08 1421 3.15 -0.05 6 0.78 34.8 1.54 -2.6 1108 3.04 -0.16 62 2 PHG negative nil positive incidental
9 RAMAMOORTHY 4701/10 51 1 blood transfusion 2 56 32 4326 3.64 25090.8 4.4 476 2.68 20 1.3 116 2.06 -4.51 1200 3.08 0.4 32000 4.51 185600 5.27 0.87 3211 3.51 0.83 68 1 normal study negative myalgia positive incidental
10 SAKTHIVEL 1687/10 36 1 blood transfusion 1 58 54 25290 4.4 146682 5.17 4272 3.63 20 1.3 116 2.06 -3.1 12342 4.09 0.46 6 0.78 34.8 1.54 -3.62 12342 4.09 0.46 72 1 normal study positive nil positive incidental
11 LOGANATHAN 5432/10 30 1 injection use 2 125 37 3781 3.58 21929.8 4.34 15138 4.18 76001 4.88 440805.8 5.64 1.3 951 2.98 -1.2 6 0.78 34.8 1.54 -2.8 8030 3.9 -0.28 32 1 normal study negative nil positive incidental
12 VASUDEVAN 3851/10 29 1 vertical 2 28 36 11755 4.07 68179 4.83 586 2.77 20 1.3 116 2.06 -2.77 149 2.17 -0.59 6 0.78 34.8 1.54 -3.29 192.7 2.28 -0.48 26 1 normal study negative nil positive screening
13 ARPUTHAM 5423/10 36 2 unknown 1 36 26 646100 5.81 3747380 6.57 48.61 1.69 20 1.3 116 2.06 -4.51 48.41 1.68 0 6 0.78 34.8 1.54 -5.03 66.96 1.83 0.14 16 1 normal study negative nil positive incidental
14 MOORTHI.V 4909/07 36 1 unknown 2 54 32 34707080 7.54 201301064 8.3 14973 4.18 24300 4.39 140940 5.15 -3.15 6450 3.81 -0.37 20000 4.3 62 5.06 -3.24 6000 3.78 -0.4 54 1 normal study negative nil positive incidental
15 SHAHIR 154/10 43 1 unknown 2 59 19 3042 3.48 17643.6 4.25 347 2.54 20 1.3 116 2.06 -2.18 152 2.18 -0.36 6 0.78 34.8 1.54 -2.71 254 2.4 -0.14 26 1 normal study negative nil positive incidental
16 VARGHEESE 0259/10 50 1 unknown 1 98 112 14999204 7.18 86995383.2 7.94 10135 4.01 6800 3.83 39440 4.6 -3.34 2342 3.37 -0.64 3132 3.5 18162.8 4.26 -3.68 3770 3.58 -0.43 82 2 normal study positive resistance positive incidental
17 GAJAPATHY RAJA 3540/09 32 1 blood transfusion 2 68 42 6400 3.81 37120 4.57 896 2.95 20 1.3 116 2.06 -2.51 490 2.69 -0.26 20 1.3 116 2.06 -2.51 450 2.65 -0.3 40 1 normal study negative myalgia positive incidental
18 VIMALANCEMARY 5231/10 45 2 blood transfusion 2 40 43 2742079 6.44 15904058.2 7.2 1956 3.29 20 1.3 116 2.06 -5.14 2462 3.39 0.1 20 1.3 116 2.06 -5.14 1432 3.16 -0.14 20 1 esophageal varices negative nil positive incidental
19 GANGADHARAN 2062/08 55 1 injection use 2 54 32 5000 3.7 29000 4.46 0.04 -1.4 20 1.3 116 2.06 -2.4 42 1.62 3.02 20 1.3 116 2.06 -2.4 72 1.86 3.26 28 1 normal study negative nil positive incidental
20 JAYARAJ 2342/10 62 1 unknown 2 84 26 23346 4.37 135406.8 5.13 23635 4.37 20 1.3 116 2.06 -3.07 24741 4.39 0.02 6 0.78 34.8 1.54 -3.59 26738 4.43 0.05 62 1 normal study negative nil positive incidental
21 JAYASEELAN 3567/11 38 1 blood transfusion 2 56 22 3456 3.54 20044.8 4.3 4210 3.62 20 1.3 116 2.06 -2.24 644.3 2.81 -0.82 6 0.78 34.8 1.54 -2.76 2221.4 3.35 -0.28 24 1 normal study negative nil positive incidental
22 CHAKRAPPAN 3623/11 25 1 tatooing 1 56 48 20500 4.31 118900 5.08 200 2.3 20 1.3 116 2.06 -3.01 136.68 2.14 -0.17 6 0.78 34.8 1.54 -3.53 188.9 2.28 -0.02 26 1 normal study negative nil positive incidental
23 MURUGAESAN 0052/10 33 1 injection use 1 45 32 132115736 8.12 76671268.8 8.88 58515 4.77 5150 3.71 29870 4.48 -4.41 41011 4.61 -0.15 2690 3.43 15602 4.19 -4.69 25117 4.4 -0.37 62 1 normal study positive nil positive incidental
24 SABAPATHY 4922/10 66 1 unknown 1 76 32 29300 4.47 169940 5.23 4117 3.61 20 1.3 116 2.06 -3.01 4500 3.65 -0.05 20 1.3 116 2.06 -3.17 5200 3.72 0.1 32 1 normal study positive nil positive incidental
25 POORNIMA 3914/10 55 2 sexual 2 46 34 2440 3.39 14152 4.15 503 2.7 20 1.3 116 2.06 -2.09 243 2.39 -0.32 20 1.3 116 2.06 -2.09 246 2.39 -0.31 16 1 normal study negative nil positive incidental
26 DEEPA 2114/10 21 2 vertical 1 44 37 170000000 8.23 986000000 8.99 125000 5.1 1747 3.24 10132.6 4.01 -4.99 92034 4.96 -0.13 1230 3.09 7134 3.85 -5.14 64799 4.81 -0.29 47 1 normal study positive nil positive screening
27 BHARATHI 3211/10 37 2 sexual 2 45 22 3500 3.54 20300 4.31 3938 3.6 85 1.93 493 2.69 -1.61 2746 3.44 -0.16 11.5 1.06 66.7 1.82 -2.48 2317 3.36 -0.23 22 1 normal study negative nil positive incidental
28 BABY 3133/10 49 2 sexual 1 36 26 24032586 7.38 139388998.8 8.14 19280 4.29 20 1.3 116 2.06 -6.08 46.86 1.67 -2.61 6 0.78 34.8 1.54 -6.6 11.47 1.06 -3.23 20 1 normal study negative nil negative incidental
29 ANUSYA 4122/10 38 2 unknown 2 82 21 2693 3.43 15619.4 4.19 7639 3.88 20 1.3 116 2.06 -2.13 9366.9 3.97 0.09 6 0.78 34.8 1.54 -2.65 6293 3.8 -0.08 18 1 normal study negative myalgia positive incidental
30 SUNDARI 5433/10 21 2 vertical 1 28 41 30036784 7.48 174213347.2 5.24 8832 3.95 1802 3.26 10451.6 4.02 -4.22 3210 3.51 -0.44 7.35 0.87 42.63 1.63 -6.61 2876 3.46 -0.49 22 1 normal study negative nil positive screening
31 PERUMAL 0177/08 34 1 injection use 2 92 87 3000 3.48 17400 4.24 2710 3.43 20 1.3 116 2.06 -2.18 2221 3.35 -0.09 6 0.78 34.8 1.54 -2.7 1841.8 3.27 -0.17 68 1 normal study negative nil positive incidental
32 VIGNESH 6067/10 20 1 vertical 2 65 32 375616 5.57 2178572.8 6.34 21000 4.32 20 1.3 116 2.06 -4.27 31818 4.5 0.18 6 0.78 34.8 1.54 -4.8 23213 4.37 0.04 62 1 normal study negative nil positive screening
33 SUDHAKARAN 0494/10 45 1 unknown 1 72 23 30000 4.48 174000 5.24 503 2.7 20 1.3 116 2.06 -3.18 202 2.31 -0.4 6 0.78 34.8 1.54 -3.7 186 2.27 -0.43 32 1 normal study negative nil positive incidental
34 RAMARAJAN 3700/08 60 1 injection use 2 75 43 5400 3.73 31320 4.5 2298 3.36 124 2.09 719.2 2.86 -1.64 2124 3.33 -0.03 6 0.78 34.8 1.54 -2.95 1876 3.27 -0.09 32 1 normal study negative nil positive incidental
35 MASILAMANI 5911/10 62 1 unknown 2 65 43 230000 5.36 1334000 6.13 876 2.94 422 2.63 2447.6 3.39 -2.74 69093 4.84 1.9 36890 4.57 213962 5.33 -0.79 568 2.75 -0.19 64 1 normal study negative nil positive incidental
36 SUBRAMANI 5614/10 63 1 blood transfusion 2 46 22 150606 5.18 873514.8 5.94 5700 3.76 20 1.3 116 2.06 -3.88 10324 4.01 0.26 20 1.3 116 2.06 -3.88 8760 3.94 0.19 28 1 normal study negative nil positive incidental
37 GANESHAN 1899/10 35 1 blood transfusion 1 89 20 25000 4.4 145000 5.16 810 2.91 190 2.28 1102 3.04 -2.12 15621 4.19 1.29 20 1.3 116 2.06 -3.1 16000 4.2 1.3 18 1 normal study positive nil positive incidental
38 MURALI 1468/06 37 1 injection use 2 49 21 4900 3.69 28420 4.45 155 2.19 20 1.3 116 2.06 -2.39 101 2 -0.19 20 1.3 116 2.06 -2.39 121 2.08 -0.11 22 2 normal study negative nil positive incidental
39 RANJITH KUMAR 1232/10 18 1 vertical 2 68 34 154027 5.19 893356.6 5.95 4376.8 3.64 20 1.3 116 2.06 -3.89 7428 3.87 0.23 6 0.78 34.8 1.54 -4.41 5570 3.75 0.1 32 1 normal study negative nil positive screening
40 MOORTHI.K 1432/10 35 1 blood transfusion 2 43 44 2320 3.37 13456 4.13 3678 3.57 20 1.3 116 2.06 -2.06 1349 3.13 -0.44 6 0.78 34.8 1.54 -0.39 1496 3.17 -0.39 32 1 normal study negative fatigue positive incidental
41 RAMASAMY 6027/10 56 1 unknown 1 82 22 10232863 7.01 59350605.4 7.77 820 2.91 60 1.78 348 2.54 -5.23 825 2.92 0 6 0.78 34.8 1.54 -6.23 842 2.93 0.01 28 1 normal study negative nil positive incidental
42 PUSHPA 5769/09 25 2 vertical 1 52 42 26230544 7.42 152137155.2 8.18 8974 3.95 58000 4.76 336400 5.53 -2.66 3560 3.55 -0.4 7000 3.85 40600 4.61 -3.57 1300 3.11 -0.84 80 1 normal study positive nil positive screening
43 DAMODHARAN 6925 55 1 blood transfusion 1 92 46 24000 4.38 139200 5.14 1230 3.09 20 1.3 116 2.06 -3.08 226 3.6 0.51 20 1.3 116 2.06 -3.08 252 2.4 -0.69 18 1 normal study negative nil positive incidental
44 WAHIDHA 185/06 36 2 unknown 2 38 32 7740 3.89 44892 4.65 10703 4.03 6 0.78 34.8 1.54 -3.11 3968 3.6 -0.43 6 0.78 34.8 1.54 -3.11 3422 3.53 -0.5 15 1 normal study negative nil positive incidental
45 SELVARAJ 6556/10 44 1 unknown 2 66 32 2456 3.39 14244.8 4.15 13031 4.11 312 2.49 1809.6 3.26 -0.9 47 1.67 -2.44 6 0.78 34.8 1.54 -2.61 14963 4.18 0.06 40 1 normal study negative nil positive incidental
46 PRAKASH 6026/10 39 1 blood transfusion 2 236 87 740790 5.87 4296582 6.63 71916 4.86 14700 4.17 85260 4.93 -1.7 2320 3.37 -1.49 10980 4.04 63684 4.8 -1.83 1980 3.3 -1.56 76 1 normal study negative myopathy positive incidental
47 ETHIRAJ 7055/10 47 1 unknown 2 114 49 10400 4.02 60320 4.78 7127 3.85 6 0.78 34.8 1.54 -3.24 1626 3.21 -0.64 6 1.3 116 1.54 -3.24 3907 3.59 -0.26 82 2 esophageal varices negative nil positive incidental
48 RAMESH 4071/02 36 1 injection use 2 62 36 2500 3.4 14500 4.16 640 2.81 20 1.3 116 2.06 -2.1 1839 3.26 0.46 20 1.3 116 2.06 -2.1 1620 3.21 0.4 32 1 normal study negative nil positive incidental
49 RAJASEKAR 5149/09 29 1 vertical 1 48 42 8382885 6.92 48620733 7.69 2E+06 6.3 68000 4.83 394400 5.6 -2.09 454 2.66 -3.64 42000 4.62 243600 5.39 -2.3 524 2.72 -3.58 82 1 normal study positive nil positive incidental
50 BABU 6772/10 28 1 injection use 2 85 31 14860 4.17 86188 4.94 22320 4.35 6 0.78 34.8 1.54 -3.39 4524 3.66 -0.69 6.15 0.79 35.67 1.55 -3.38 5030 3.7 -0.65 25 1 normal study negative nil positive screening
51 RAMESH 2216/08 30 1 blood transfusion 2 62 42 4200 3.62 24360 4.39 111 2.05 20 1.3 116 2.06 -2.32 54 1.73 -0.31 6 0.78 34.8 1.54 -2.85 77 1.89 -0.16 40 1 normal study negative nil positive incidental
52 CHANDRA 7405/11 45 2 unknown 2 43 32 329536 5.52 1911303 6.28 37039 4.57 2000 3.3 11600 4.06 -2.22 21502 4.33 -0.24 440 2.64 2552 3.41 -2.87 22562 4.35 -0.22 34 1 normal study negative nil positive incidental
53 LOGANAYAKI 1022/05 40 2 unknown 2 42 21 26651 4.43 154575.8 5.19 4.64 0.67 4E+08 8.58 2186600000 9.34 4.15 351.27 2.55 1.88 2E+06 6.39 1.4E+07 7.15 1.96 686 2.84 2.17 68 1 normal study negative myopathy positive incidental
54 KANNAGI 1034/05 30 2 sexual 2 38 24 2440 3.39 14152 4.15 2126 3.33 6 0.78 34.8 1.54 -2.61 1897 3.28 0.05 6 0.78 34.8 1.54 -2.61 169 2.23 -1.1 14 1 normal study negative nil positive incidental
55 DEIVASIGAMANI 639/10 50 1 unknown 2 52 24 2780 3.44 16124 4.21 939 2.97 20 1.3 116 2.06 -2.14 1246 3.1 0.12 6 0.78 34.8 1.54 -2.67 1022 3.01 0.04 28 1 normal study negative nil positive incidental
56 RAVI KUMAR 7302/10 45 1 blood transfusion 2 140 40 8000 3.9 46400 4.67 2282 3.36 20 1.3 116 2.06 -2.6 2022 3.31 -0.05 6 0.78 34.8 1.54 -3.12 1824 3.26 -0.1 34 1 normal study negative myalgia positive incidental
57 KANNAN 7251/10 23 1 vertical 2 40 76 434348 5.64 2519218.4 6.4 117425 5.97 31 1.49 179.8 2.25 -4.15 68373 4.83 -0.23 13.5 1.13 78.3 1.89 -4.51 60000 4.78 -0.29 32 1 normal study negative nil positive screening
58 JAYASEKARAN 5136/10 42 1 unknown 1 82 43 28000 4.45 162400 5.21 6628 3.82 15.4 1.19 89.32 1.95 -3.26 7452 3.87 0.05 6 0.78 34.8 1.54 -3.67 6500 3.81 -0.01 48 2 normal study positive nil positive incidental
59 NEDUNCHEZIAN 7538 56 1 unknown 2 62 32 5174757 6.71 30013590.6 7.48 2908 3.46 40.91 1.61 237.278 2.38 -5.1 2630 3.42 -0.04 50 1.7 290 2.46 -5.01 1855 3.27 -0.2 35 1 normal study negative nil positive incidental
60 THANIGACHALAM 8361/10 45 1 injection use 2 76 28 24000 4.38 139200 5.14 373 2.57 306 2.49 1774.8 3.25 -1.89 124 2.09 -0.48 6 0.78 34.8 1.54 -3.6 387 2.59 0.02 1 normal study negative nil positive incidental
61 SELVAKUMAR 141/09 29 1 vertical 1 36 29 170000000 8.23 986000000 8.99 125000 5.1 185 2.27 1073 3.03 -5.96 552 2.74 -2.35 6070 3.78 35206 4.55 -4.45 41724 4.62 -0.48 63 1 normal study positive fatigue positive screening
62 ARJUNAN 329/11 60 1 blood transfusion 1 74 116 321754 5.51 1866173.2 6.27 2898 3.46 6 0.78 34.8 1.54 -4.73 1199 3.51 0.04 1411 3.15 83.8 3.91 -2.36 964.64 2.98 -0.48 24 1 normal study negative nil positive incidental
63 SUNDARAM 728/10 53 1 injection use 1 48 63 487362 5.69 2826699.6 6.45 1189 3.08 12000 4.08 69600 4.84 -1.61 23000 4.36 1.29 10900 4.04 63220 4.8 -1.65 13141 4.12 1.04 82 1 normal study positive resistance positive incidental
64 PARIMALA 319/11 60 2 sexual 1 37 32 24582222 7.39 142576887.6 8.15 1017 3.01 5400 3.73 31320 4.5 -3.66 344 2.54 -0.47 20 0.78 34.8 2.06 -6.09 240 2.38 -0.63 18 1 normal study negative nil positive incidental
Baseline 24th Week 48th week
65 RAMACHANDRAN 626/11 65 1 unknown 2 45 24 36958 4.57 214356.4 5.33 10295 4.01 240 2.38 1392 3.14 -2.19 7800 3.89 -0.12 20 1.3 116 2.06 -3.27 6824 3.83 -0.18 23 1 normal study negative nil positive incidental
66 MANOHARAN 264/11 56 1 unknown 2 152 42 10359634 7.02 60085877.2 7.78 10141 4.01 680 2.83 3944 3.6 -4.18 9840 3.99 -0.01 20 1.3 116 2.06 -5.71 6800 3.83 -0.17 68 1 normal study negative nil positive incidental
67 DHARANI KARASI 932/10 42 2 blood transfusion 1 66 20 533175 5.73 3092415 6.49 4952 3.69 7.57 0.88 43.9 1.64 -4.85 7545 3.88 0.18 6 0.78 34.8 1.54 -4.95 6924.3 3.84 0.15 64 1 normal study positive nil positive incidental
68 SUBRAMANIYAM 2369/10 60 1 unknown 1 65 50 23177706 7.37 134430694 8.13 1688 3.23 18200 4.26 105560 5.02 -3.1 5453 3.74 0.51 14200 4.15 82360 4.92 -3.21 4045.4 3.61 0.38 58 2 normal study positive nil positive incidental
69 SURESH KUMAR 1115/11 30 1 injection use 1 212 58 9268972 6.97 53760037.6 7.73 17461 4.24 8.86 0.95 51.38 1.71 -6.02 37130 4.57 0.33 6 0.78 34.8 1.54 -6.19 49436 4.69 0.45 82 1 normal study positive nil positive incidental
70 RAMADOSS 3575/10 44 1 blood transfusion 1 138 130 129846328 8.11 753108702.4 8.88 125000 5.1 77.6 1.89 450.08 2.65 -6.22 1450 3.16 -1.94 6 0.78 34.8 1.54 -7.34 1000 3 -2.1 32 1 PHG negative nil positive incidental
71 ARUMUGAM 860/11 28 1 vertical 1 33 50 170000000 8.23 986000000 8.99 121833 5.09 33200 4.52 192560 5.28 -3.71 56923 4.76 -0.33 2340 3.37 13572 4.13 -4.86 48924 4.69 -0.4 38 1 normal study positive myalgia positive screening
72 GAJENDIRAN 1764/11 52 1 injection use 1 60 36 12395264 7.09 71892531.2 7.86 13816 4.14 6 0.78 34.8 1.54 -6.32 891 2.95 -1.99 6 0.78 34.8 1.54 -6.32 568 2.75 -1.39 26 1 normal study negative nil positive incidental
73 ANANDHAN 1725/11 65 1 unknown 1 56 42 7086425 6.85 41101265 7.61 781 2.89 2400 3.38 13920 4.14 -3.47 432 2.64 -0.26 20 1.3 116 2.06 -5.55 400 2.6 -0.29 34 1 normal study negative nil positive incidental
74 SIVA 1012/11 41 1 injection use 1 170 65 5069172 6.7 29401197.6 7.47 1275 3.11 230 2.36 1334 3.13 -4.34 1040 3.02 -0.09 20 1.3 116 2.06 -5.4 820 2.91 -0.19 24 1 normal study negative nil positive incidental
75 SRINIVASAN 890/11 36 1 unknown 1 82 34 2057013 6.31 11930675.4 7.08 61910 4.79 6950 3.84 40310 4.61 -2.47 23903 4.38 -0.41 420 2.62 2436 3.39 -3.69 32560 4.51 -0.28 62 2 normal study positive nil positive incidental
76 venkatesan 2191/11 29 1 vertical 1 75 42 102523 5.01 594633.4 5.77 54830 4.74 560 2.75 3248 3.51 -2.26 2690 3.43 -1.31 20 1.3 116 2.06 -3.71 1480 3.17 -1.57 35 2 normal study negative nil positive screening
77 shanthi 1648/11 39 2 blood transfusion 1 86 21 2689058 6.43 15596536.4 7.19 4602 3.66 60.8 1.78 352.64 2.55 -4.65 40.54 1.61 -2.06 13.9 1.14 80.62 1.91 -5.29 346.11 2.54 -1.12 18 1 normal study negative myalgia positive incidental
78 kali 275/10 49 1 blood transfusion 1 56 77 15464257 7.19 89692690.6 7.95 4434 3.65 2454 3.39 14233.2 4.15 -3.8 30700 4.49 0.84 20 1.3 116 2.06 -5.89 24500 4.39 0.74 58 1 PHG positive nil positive incidental
79 N.Govindan 2346/11 50 1 injection use 2 64 101 2488 3.4 14430.4 4.16 330 2.52 1E+05 5.11 747620 5.87 1.71 650 2.81 0.29 3E+05 5.48 1734200 6.24 2.08 265.64 2.42 -0.09 72 1 normal study negative resistance positive incidental
80 sumathi 6976/10 58 2 unknown 2 61 72 6890 3.84 39962 4.6 43.95 1.64 890 2.95 5162 3.71 -0.89 210 2.32 0.68 20 1.3 116 2.06 -2.54 180 2.26 0.61 28 1 normal study negative nil positive incidental
81 rajendiran 222/11 42 1 unknown 1 84 62 170000000 8.23 986000000 8.99 125000 5.1 1400 3.15 8120 3.91 -5.08 8200 3.91 -1.18 20 1.3 116 2.06 -6.93 7046.9 3.85 -1.25 68 1 normal study positive nil positive incidental
82 MURUGADOSS 2135/11 33 1 blood transfusion 2 42 65 8000 3.9 46400 4.76 15512 4.19 6 0.78 34.8 1.54 -3.12 4070 3.61 -0.58 6 0.78 34.8 1.54 -3.12 8697.7 3.94 -0.25 26 1 normal study negative nil positive incidental
83 rajasekar.m 3089/11 60 1 unknown 1 51 74 28350 4.45 164430 5.39 5818 3.64 6150 3.79 35670 4.55 -0.66 18923 4.28 0.51 350 2.54 2030 3.31 -1.91 12000 4.08 0.31 32 1 normal study positive nil positive incidental
84 Shahul Hameed 2902/11 29 1 vertical 1 82 42 170000000 8.23 986000000 8.99 125000 5.1 1040 3.02 6032 3.78 -5.21 53591 4.73 -0.37 6.42 0.81 37.2 1.57 -7.42 2576.8 3.41 -1.69 80 1 PHG positive fatigue positive screening
85 Mallika Begum 2859/11 46 2 unknown 2 60 23 4570 3.66 26506 4.42 2460 3.39 180 2.26 1044 3.02 -1.4 1250 3.1 -0.29 6 0.78 34.8 1.54 -2.88 1100 3.04 -0.35 16 2 normal study negative nil positive incidental
86 Gunasekaran 2906/11 54 1 unknown 2 82 49 1397652 6.15 8106381.6 6.91 4783 3.68 122 2.09 707.6 2.85 -4.06 2222 3.35 -0.33 20 1.3 116 2.06 -4.84 1800 3.26 -0.42 26 1 normal study negative nil positive incidental
87 Adhikesavan 3079/11 52 1 tatooing 2 78 32 130 2.11 754 2.88 14231 4.15 6 0.78 34.8 1.54 -1.34 6128 3.79 -0.37 6 0.78 34.8 1.54 -1.34 5860 3.77 -0.39 32 1 PHG negative myalgia positive incidental
88 Sivakami 3010/11 36 2 unknown 1 52 22 42000 4.62 243600 5.39 4320 4.03 426 2.63 2470.8 3.39 -1.99 2200 3.34 -0.29 20 1.3 116 2.06 -3.32 1800 3.26 -0.38 32 1 normal study negative nil positive incidental
89 Sathiya 2472/11 25 2 vertical 2 34 45 43363640 7.64 251509112 8.4 55064 4.74 6 0.78 34.8 1.54 -6.86 73084 4.86 0.12 6 0.78 34.8 1.54 -6.86 52000 4.72 -0.02 64 1 normal study negative nil positive screening
90 Ameen 3099/11 34 1 tatooing 1 92 43 62000 4.79 359600 5.56 5230 3.72 84 1.92 487.2 2.69 -2.87 2450 3.39 -0.33 20 1.3 116 2.06 -3.49 2000 3.3 -0.42 32 1 normal study negative nil positive incidental
91 Sivachandran 3157/11 25 1 vertical 1 86 52 84445 4.93 489781 5.69 10700 4.03 6 0.78 34.8 1.54 -4.15 22954 4.36 -0.33 4030 3.61 23374 4.37 -1.32 66216 4.82 0.79 68 1 normal study positive resistance positive screening
92 Mohandass 4177/11 48 1 blood transfusion 2 84 24 2640 3.42 15312 4.19 351 2.55 240 2.38 1392 3.14 -1.04 380 2.58 0.03 20 1.3 116 2.06 -2.12 320 2.51 -0.04 24 1 normal study negative nil positive incidental
93 Jaykumar 4197/11 46 1 unknown 1 84 42 3620000 6.56 20996000 7.32 1806 3.26 18 1.26 104.4 2.02 -5.3 1773 3.25 -0.01 6 0.78 34.8 1.54 -5.78 1450 3.16 -0.1 36 1 normal study negative nil positive incidental
94 Ettiyappan 4310/11 46 1 injection use 2 72 23 110000000 8.04 638000000 8.8 41923 4.62 1890 3.28 10962 4.04 -4.76 16068 4.21 -0.42 163 2.21 945.4 2.98 -5.83 33000 4.52 -0.1 35 1 normal study negative nil positive incidental
95 Sabarish 4885/11 34 1 blood transfusion 1 76 46 48000 4.68 278400 5.44 6280 3.8 250 2.4 1450 3.16 -2.28 2140 3.33 -0.47 20 1.3 116 2.06 -3.38 1890 3.28 -0.52 26 1 normal study negative nil positive incidental
96 Govindasamy 4510/11 65 1 unknown 1 223 116 110000000 8.04 638000000 8.8 20929 4.32 1200 3.08 6960 3.84 -4.96 2500 3.4 -0.92 280 2.45 1624 3.21 -5.59 2100 3.32 -1 38 1 normal study negative nil positive incidental
97 Jothi 803/11 47 2 unknown 1 43 29 56000 4.75 324800 5.51 6780 3.83 112 2.05 649.6 2.81 -2.7 3500 3.54 -0.29 20 1.3 116 2.06 -3.45 3800 3.58 -0.25 26 1 normal study positive nil positive incidental
98 Latha 5453/11 36 2 sexual 1 32 28 124000 5.09 719200 5.86 1136862 6.06 900 2.95 5220 3.72 -2.14 41747 4.62 -1.44 400 2.6 2320 3.37 -2.49 35000 4.54 -1.51 46 1 normal study positive nil positive incidental
99 Kanniyappan 192/08 38 1 blood transfusion 1 120 50 30004 4.48 174023.2 5.24 4800 3.68 20 1.3 116 2.06 -3.18 2700 3.43 -0.25 20 1.3 116 2.06 -3.19 2450 3.39 -0.29 34 2 normal study negative nil positive incidental
100 Abdul Jabbar 5540/11 34 1 vertical 1 84 42 120000 5.08 696000 5.84 8760 3.94 20000 4.3 116000 5.06 -0.78 14670 4.17 0.22 12500 4.1 72500 4.86 -0.98 13450 4.13 0.19 72 1 normal study positive nil positive screening
